骨髄増殖性腫瘍に対す...

骨髄増殖性腫瘍に対するJAK2阻害剤の有効性とruxolitinibのFDA承認 (特集 血液腫瘍に対して開発中の注目すべき新薬)

Icons representing 記事

骨髄増殖性腫瘍に対するJAK2阻害剤の有効性とruxolitinibのFDA承認

(特集 血液腫瘍に対して開発中の注目すべき新薬)

Call No. (NDL)
Z19-585
Bibliographic ID of National Diet Library
024269319
Material type
記事
Author
幣 光太郎
Publisher
東京 : 科学評論社
Publication date
2013-01
Material Format
Paper
Journal name
血液内科 = Hematology / 血液内科編集委員会 編 66(1)=415:2013.1
Publication Page
p.7-14
View All

Holdings of Libraries in Japan

This page shows libraries in Japan other than the National Diet Library that hold the material.

Please contact your local library for information on how to use materials or whether it is possible to request materials from the holding libraries.

other

  • CiNii Research

    Search Service
    You can check the holdings of institutions and databases with which CiNii Research is linked at the site of CiNii Research.

Bibliographic Record

You can check the details of this material, its authority (keywords that refer to materials on the same subject, author's name, etc.), etc.

Paper

Material Type
記事
Author/Editor
幣 光太郎
Author Heading
Alternative Title
Efficacy of JAK2 inhibitor for the treatment of myeloproliferative neoplasms and FDA approval of ruxolitinib
Periodical title
血液内科 = Hematology / 血液内科編集委員会 編
No. or year of volume/issue
66(1)=415:2013.1
Volume
66
Issue
1